2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1629

Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 2484

Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients
Abstract Number: 22

Adenosine a_2A Receptor (A2AR) Stimulation Inhibits Osteoclast Differentiation and Promotes Osteoblast Formation By Regulation of Axon Guidance Proteins
Abstract Number: 2947

Adenosine a_2A Receptor As a Potential New Therapeutic Target for the Prevention/Treatment of Osteoarthritis
Abstract Number: 1729

Adenosine A2A Receptor (A2AR) Promotes Collagen Type 3 Expression Via β-Catenin Activation
Abstract Number: 19

Adenosine Receptors Stimulate Bone Regeneration
Abstract Number: 2381

Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
Abstract Number: 2316

Adherence to Denosumab in a Large Healthcare System
Abstract Number: 2382

Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures
Abstract Number: 181

Adherence to Treatment Recommendations of Gout: A Patient Survey in China
Abstract Number: 966

Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism
Abstract Number: 532

Adipose Tissue Is Prominent in Salivary Glands of Sjögren’s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs
Abstract Number: 1305

Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus
Abstract Number: 478

Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Abstract Number: 1828

Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].